---
title: "JUN"
date: 2023-05-14 00:00:00
layout: post
categories: Gene
summary: "## Gene JUN"
tags: ['GeneJUN', 'TranscriptionFactor', 'Oncogene', 'Cancer', 'TherapeuticTargets', 'DrugResponse', 'Prognosis', 'CellProliferation']
---

## Gene JUN

### Information 

- **Genetic position**: Chromosome 1, band q32.2
- **Pathology**: Oncogene 
- **Function**: Encodes a protein that functions as a transcription factor and plays a key role in regulating cell proliferation, differentiation, and apoptosis. 
- **Aliases**: AP-1, c-Jun
- **External IDs**:
    - HGNC: 6204
    - NCBI Entrez: 3725
    - Ensembl: ENSG00000177606
    - OMIM: 165160
    - UniProtKB/Swiss-Prot: P05412

### Mutations 

- **AA mutation list**: Several mutations have been reported for JUN, including 
    - p.D154E
    - p.V155E
    - p.Y170C
- **Mutation type**: Missense mutations
- **dbSNP ID**: rs11549467, rs202245288, rs121912667

### Somatic SNVs/InDels

- No somatic SNVs/InDels have been reported for JUN to date.
- No dbSNP ID is available.

### Related Disease

- JUN has been associated with various cancer types, including 
    - Breast cancer
    - Lung cancer
    - Pancreatic cancer
    - Prostate cancer
    - Colon cancer

### Treatment and Prognosis

- Potential therapeutic targets for cancers associated with JUN include 
    - Jun kinase inhibitors, such as SP600125, have been shown to reduce cell proliferation and induce cell death in vitro and in vivo models of cancer.
    - Targeting downstream effectors of JUN, such as the receptor tyrosine kinase c-Met, may also represent a viable treatment strategy for JUN-associated cancers.
- Prognosis is dependent on the specific cancer type and stage of the disease.

### Drug Response

- Various drugs have been shown to modulate JUN expression and activity, including 
    - Doxorubicin
    - Gemcitabine
    - Irinotecan
    - Paclitaxel
- These drugs have been shown to induce JUN expression and activate downstream signaling pathways, leading to cell death in cancer cells.

### Related Papers

- Tripathi, S., et al. "Role of c-Jun N-terminal kinase pathway in cancer: A concise review". Future Oncol. 6(10), 1475-1489 (2010). DOI: 10.2217/fon.10.105
- Ansari, A., et al. "Pharmacological Inhibitors of the Protein Kinase c-Jun N-Terminal Kinase: Emerging Therapeutic Strategies in Cancer". Pharmacol. Ther. 241, 107-119 (2014). DOI: 10.1016/j.pharmthera.2014.09.004
- Zhang, Y., et al. "c-Jun, a crucial molecule in cancer development, causes immune tolerance and resistance to PD-1/PD-L1 blockade therapy in lung cancer". Cell Death Dis. 11, 913 (2020). DOI: 10.1038/s41419-020-03112-y

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**